[go: up one dir, main page]

WO2006008173A3 - Formulations pharmaceutiques - Google Patents

Formulations pharmaceutiques Download PDF

Info

Publication number
WO2006008173A3
WO2006008173A3 PCT/EP2005/007991 EP2005007991W WO2006008173A3 WO 2006008173 A3 WO2006008173 A3 WO 2006008173A3 EP 2005007991 W EP2005007991 W EP 2005007991W WO 2006008173 A3 WO2006008173 A3 WO 2006008173A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhalation
pharmaceutical formulations
salts
administration
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/007991
Other languages
English (en)
Other versions
WO2006008173A2 (fr
Inventor
Michael Simon Anson
Derek Leslie Crookes
Harish Shivprasad Trivedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of WO2006008173A2 publication Critical patent/WO2006008173A2/fr
Publication of WO2006008173A3 publication Critical patent/WO2006008173A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a trait à des sels d'un sucre polymérique biodégradable comportant des groupes acides et un agent pharmaceutiquement actif comportant un ou des groupes basiques, et à des formulations pharmaceutiques desdits sels adaptées pour une administration par inhalation.
PCT/EP2005/007991 2004-07-22 2005-07-20 Formulations pharmaceutiques Ceased WO2006008173A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0416397.8 2004-07-22
GB0416397A GB0416397D0 (en) 2004-07-22 2004-07-22 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
WO2006008173A2 WO2006008173A2 (fr) 2006-01-26
WO2006008173A3 true WO2006008173A3 (fr) 2006-05-26

Family

ID=32922634

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007991 Ceased WO2006008173A2 (fr) 2004-07-22 2005-07-20 Formulations pharmaceutiques

Country Status (2)

Country Link
GB (1) GB0416397D0 (fr)
WO (1) WO2006008173A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928089B2 (en) 2003-09-15 2011-04-19 Vectura Limited Mucoactive agents for treating a pulmonary disease

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
US20100099651A1 (en) * 2006-10-26 2010-04-22 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP1921070A1 (fr) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG heterocycles bicycliques, medicaments á base de ces composes, leur usage et procédé pour leur preparation
WO2009087224A1 (fr) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines utilisés en tant qu'inhibiteurs de kinase
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
DK3578169T3 (da) 2009-02-26 2024-07-22 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1R)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
MX2013009767A (es) 2011-02-25 2013-10-01 Irm Llc Compuestos y composiciones como inhibidores de trk.
CN117679423A (zh) * 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555898A2 (fr) * 1985-04-05 1993-08-18 FIDIA S.p.A. Médicaments pour l'application non-topique
JPH1180032A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 複合体
WO2002051380A1 (fr) * 2000-12-22 2002-07-04 Audit Institute For Medical Services And Quality Assurance Gmbh Nouvelle composition pharmaceutique de principes actifs solubles dans l'eau ou peu solubles dans l'eau
EP1407776A1 (fr) * 2002-10-10 2004-04-14 Giuseppe Petrigni Une composition pharmaceutique colloide comprenant des biopolymères d'acide hyaluronique pour le traitement des maladies respiratoires

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0555898A2 (fr) * 1985-04-05 1993-08-18 FIDIA S.p.A. Médicaments pour l'application non-topique
JPH1180032A (ja) * 1997-09-12 1999-03-23 Dai Ichi Seiyaku Co Ltd 複合体
WO2002051380A1 (fr) * 2000-12-22 2002-07-04 Audit Institute For Medical Services And Quality Assurance Gmbh Nouvelle composition pharmaceutique de principes actifs solubles dans l'eau ou peu solubles dans l'eau
EP1407776A1 (fr) * 2002-10-10 2004-04-14 Giuseppe Petrigni Une composition pharmaceutique colloide comprenant des biopolymères d'acide hyaluronique pour le traitement des maladies respiratoires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199922, Derwent World Patents Index; Class B04, AN 1999-261460 *
PATENT ABSTRACTS OF JAPAN vol. 1999, no. 08 30 June 1999 (1999-06-30) *
SURENDRAKUMAR K ET AL: "Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 91, no. 3, 4 September 2003 (2003-09-04), pages 385 - 394, XP004447921, ISSN: 0168-3659 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7928089B2 (en) 2003-09-15 2011-04-19 Vectura Limited Mucoactive agents for treating a pulmonary disease

Also Published As

Publication number Publication date
WO2006008173A2 (fr) 2006-01-26
GB0416397D0 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
WO2006084164A8 (fr) Systeme d'administration a retention gastrique et a liberation lente
WO2006101882A3 (fr) Formulations galeniques de medicaments, dispositifs et procedes associes
WO2008120207A3 (fr) Compositions pour administration nasale
WO2007087431A3 (fr) Pulvérisation sublinguale de fentanyle
WO2007002597A3 (fr) Formulations a liberation modifiee d'un sel de bupropion
WO2007036952A3 (fr) Nouvelle forme posologique a liberation soutenue
WO2009017837A3 (fr) Aérosol sublingual de fentanyl
AP2005003318A0 (en) Pharmaceutical compositions comprising a basic respectively acidic drug coumpound, a surfactant and a physiologically tolerable watersoluble acid respectively base.
IL195269A0 (en) Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic
WO2012022919A3 (fr) Formulations à base de nalbuphine et leurs utilisations
NO20080827L (no) Faste doseringsformuleringer av narkotiske legemidler som har forbedret bukal adsorpsjon
WO2006008173A3 (fr) Formulations pharmaceutiques
WO2006138735A3 (fr) Compositions de gel pour administration topique
WO2008003050A3 (fr) Formulations de nitrate de gallium
WO2007144169A3 (fr) Dérivés d'entacapone
EP2316420A8 (fr) Procédé pour réduire la douleur
UA96622C2 (ru) Твердые лекарственные формы, которые содержат алискирен, изготовленные способом сухого гранулирования
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2010052466A8 (fr) Composition pharmaceutique en aérosol
WO2007083190A3 (fr) Extrait d'helychrisum insoluble dans l'eau, et procédés d'élaboration et d'utilisation correspondants
EP1584335A3 (fr) Combinaison de substances actives comprenant un composé carbinol et un opioïde
WO2005046637A3 (fr) Formulations pharmaceutiques utilisant des sphingolipides a chaine courte et leur application
WO2011058336A3 (fr) Comprimé
WO2010029093A3 (fr) Compositions destinées à une administration percutanée
WO2008060546A3 (fr) Formulations orales

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase